Researchers at the University of Alabama at Birmingham have shown — for the first time — that established lung fibrosis can be reversed using a drug treatment that targets cell metabolism.
This novel finding, reported in the journal Nature Medicine, is important because, despite significant advances to reveal the pathological mechanisms of persistent fibrosis, effective treatment interventions are lacking.
Pulmonary fibrosis can develop after lung injuries like infections, radiation or chemotherapy, or it can have an unknown cause, as in idiopathic pulmonary fibrosis, or IPF. IPF is a progressive, and ultimately fatal, lung disorder that strikes more than 150,000 patients a year in the United States and more than 5 million worldwide.
In experiments using lung tissues from patients with IPF, mouselung fibroblasts and a murine model of lung fibrosis, a team led by Jaroslaw Zmijewski, Ph.D., and Victor Thannickal, M.D., showed the reversal of lung fibrosis and the underlying cellular mechanisms affected by the drug treatment.
Zmijewski and Thannickal are, respectively, associate professor and professor in the UAB Department of Medicine. Zmijewski serves as research director for the Translational Program in ARDS. Thannickal holds the Ben Vaughan Branscomb Chair of Medicine in Respiratory Disease and is director of the UAB Division of Pulmonary, Allergy and Critical Care Medicine.
Activation of AMPK in myofibroblasts from lungs of humans with IPF, using the drug metformin or another activator called AICAR, led to lower fibrotic activity. AMPK activation also enhanced the production of new mitochondria, the organelles in cells that produce energy, in the myofibroblasts, and it normalized the cells’ sensitivity to apoptosis. |
Interestingly, the drug that accelerated the resolution of lung fibrosis is metformin, which is a safe and widely used agent for non-insulin-dependent diabetes.
The research focused on AMP-activated protein kinase (AMPK), an enzyme that senses energy state in the cell and regulates metabolism. Zmijewski, Thannickal and colleagues found that AMPK activity was lower in myofibroblast cells within fibrotic regions of human lung tissue from IPF patients. Myofibroblasts deposit extracellular collagen fiber as part of the fibrosis process. These myofibroblasts were metabolically active and were resistant to the programmed cell death called apoptosis, a natural process that removes more than 50 billion damaged or aged cells in adults each day.
Activation of AMPK in myofibroblasts from lungs of humans with IPF, using the drug metformin or another activator called AICAR, led to lower fibrotic activity. AMPK activation also enhanced the production of new mitochondria, the organelles in cells that produce energy, in the myofibroblasts, and it normalized the cells’ sensitivity to apoptosis.
Using a mouse model for lung fibrosis elicited by the anti-cancer drug bleomycin, the research team found metformin treatment, starting three weeks after lung injury and continuing for five weeks, accelerated the resolution of well-established fibrosis. Such resolution was not apparent in AMPK-knockout mice, showing that the effect of metformin was AMPK-dependent.
“Together, our studies support the concept that AMPK may function as a critical metabolic switch in promoting resolution of established fibrosis by shifting the balance from anabolic to catabolic metabolism,” the researchers wrote. “Additionally, we provide proof-of-concept that activation of AMPK by metformin or other pharmacologic agents that activate these pro-resolution pathways may be a useful therapeutic strategy for progressive fibrotic disorders.”
Anabolic metabolism builds up molecules in the cell from smaller units, while catabolic metabolism tears larger molecules into smaller pieces.
Learn more: Metformin reverses established lung fibrosis
The Latest on: Pulmonary fibrosis
[google_news title=”” keyword=”pulmonary fibrosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pulmonary fibrosis
- Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patientson May 14, 2024 at 7:39 am
Pliant Therapeutics Inc (NASDAQ:PLRX) announced topline data from a Phase 2a PET Imaging trial of bexotegrast (PLN-74809) evaluating change in total collagen levels in the lungs of patients with ...
- Carisma Therapeutics Showcases Breakthrough in Liver and Lung Fibrosis Treatmenton May 13, 2024 at 7:00 am
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM), a pioneering biotechnology firm, has unveiled promising preclinical data for an innovative treatment approach to liver fibrosis, a ...
- GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Updateon May 13, 2024 at 6:13 am
Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) ...
- Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conferenceon May 13, 2024 at 5:56 am
Title: Effectiveness of brilaroxazine on functional and underlying pathological inflammation and fibrosis parameters in bleomycin-induced idiopathic pulmonary fibrosis model using male sprague dawley ...
- Research shows the impact of social deprivation and distance on pulmonary fibrosis survivalon May 10, 2024 at 12:32 am
Patients with pulmonary fibrosis from the poorest areas had more severe symptoms by the time they saw a hospital doctor and had a poorer survival rate than those living in wealthier areas, according ...
- Health First’s Pulmonary Rehab Builds Strength, Capacity for Breathing Impairedon May 9, 2024 at 10:49 pm
“Pulmonary Rehab strengthens the muscles as it endeavors to impart essential skills for tracking oxygen saturation, breathing techniques such as pursed-lip breathing, understanding their disease ...
- Patients with chronic lung disease who live farther from a hospital found to have poorer survival rateon May 9, 2024 at 12:24 pm
Patients with pulmonary fibrosis from the poorest areas had more severe symptoms by the time they saw a hospital doctor and had a poorer survival rate than those living in wealthier areas, according ...
- Looking back on the 8 years that followed my IPF diagnosison May 9, 2024 at 7:00 am
The anniversary of an IPF diagnosis is always a time for reflection. Columnist Charlene Marshall shares her thoughts on her own anniversary.
- New study probes macrophages' role in developing pulmonary fibrosison April 11, 2024 at 5:00 pm
A new University at Buffalo-led study sheds light on this mystery and opens new paths to study pulmonary fibrosis, advancements that could ultimately lead to more effective medicine and therapies ...
via Bing News